| Filed On | Filing |
|---|---|
| 28 May 2021 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On April 19, 2021, Abeona Therapeutics Inc. (the “Company”) filed a Current Report on Form 8-K disclosing under Item 5.02 that Leila Alland, M.D. and Donald Wuchterl were appointed to serve on the Board of Directors (the “Board”) of the ... |
| 09 Oct 2018 |
8-K/A: Departure/Election of Directors or Officers; Compensation
Congratulations once again on your retirement. I want to thank you for your years of service and many contributions. This letter of agreement outlines the terms of your separation from employment with Abeona Therapeutics Inc. (the “Compa... |
| 14 May 2018 |
8-K/A: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(a) On May 10, 2018, Timothy J. Miller, Ph.D., resigned as a class 3 director. Dr. Miller remains President and Chief Scientific Officer of the Company. Dr. Miller did not have any disagreement with the Company on any matter relating to ... |
| 04 Jun 2015 |
8-K/A: Financial Statements and Exhibits
The report accompanying these financial statements was issued by BDO USA, LLP, a Delaware limited liability partnership and the U.S. member of BDO International Limited, a UK company limited by guarantee. |
| 13 May 2015 |
8-K/A: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation
On May 7, 2015, the shareholders of PlasmaTech Biopharmaceuticals, Inc. approved the 2015 Equity Incentive Plan, under which 5,000,000 shares of common stock shall be available for issuance to our officers and employees, non-employee mem... |
| 27 Apr 2015 |
8-K/A: Unregistered Sales of Equity Securities; Other Events
DALLAS, TX and NEW YORK, NY - April 24, 2015 - PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, announced today it had closed an u... |
| 26 Aug 2009 |
8-K/A: Financial Statements and Exhibits
Consolidated Statement of Operations for Year Ended December 31, 2008 F-3 |
| 22 Sep 2008 |
8-K/A: Financial Statements and Exhibits
The audited consolidated financial statements of Somanta Pharmaceuticals, Inc. and the unaudited interim financial statements of Somanta Pharmaceuticals, Inc. are hereby incorporated by reference. The statements were audited by Stonefiel... |
| 17 Jun 2008 |
8-K/A: Financial Statements and Exhibits
- Acquisition of Four Potent Anti-cancer Products Fills Out Robust Pipeline - |
| 23 Apr 2007 |
8-K/A: Entry into a Material Definitive Agreement; Other Events
ARTICLE I. THE MERGER................................................................................ 2 |
| 16 Nov 2004 |
8-K/A: Results of Operations and Financial Condition
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| 04 Oct 1999 |
8-K/A: Completion of Acquisition or Disposition of Assets
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 |
Loading...